With severe vision loss, you may only be able to see things straight in front of you (sometimes called “tunnel vision”). Some people can have severe loss particularly to their ability to see to the side when looking straight ahead (peripheral vision). SABRIL can damage the vision of anyone who takes it.Your healthcare provider will explain the details of this program to you. Because SABRIL might cause permanent vision loss, it is available to healthcare providers and patients only under a special program called the Vigabatrin Risk Evaluation and Mitigation Strategy (REMS) Program.It may even happen after treatment has stopped. It could happen soon after starting SABRIL or any time during treatment. It is not possible for your healthcare provider to know when vision loss will happen. Your risk of vision loss may be higher the more SABRIL you take daily and the longer you take it.You are at risk for vision loss with any amount of SABRIL.WARNING: PERMANENT VISION LOSS See Medication Guide and full Prescribing Information for complete information. Indicate “Dispense as written (DAW)” or “Brand medically necessary” on the form (per your state regulations) Alternatively, if you do not want to submit your Sabril prescription through SHARE Plus, you can send a prescription directly to a certified specialty pharmacy found on the Vigabatrin REMS website.Completing this form allows you and your patients/caregivers an opportunity to benefit from the support offered by SHARE Plus We encourage you to complete this optional Sabril Prescription Form.Alternatively, you can send a prescription directly to a certified specialty pharmacy found on the Vigabatrin REMS website. We encourage you to complete this optional Sabril Prescription Form. An optional form, the Sabril Prescription Form, is available on this Sabril website for prescribers who choose to submit the prescription through Lundbeck’s SHARE Plus program.Submitting Your Patient’s Sabril ® (vigabatrin) Prescription By clicking on the link below, prescribers will be taken to the website that manages the process and contains the required vigabatrin REMS forms. The Vigabatrin REMS Program is required by the FDA to ensure informed risk-benefit decisions before initiating treatment, and to ensure appropriate use of vigabatrin while patients are treated. The US Food and Drug Administration (FDA) has approved a single shared Risk Evaluation and Mitigation Strategy (REMS) program for all vigabatrin products.
0 Comments
Leave a Reply. |